Dynavax Technologies (NASDAQ:DVAX) Earns “Buy” Rating from HC Wainwright

Dynavax Technologies (NASDAQ:DVAX)‘s stock had its “buy” rating reiterated by analysts at HC Wainwright in a research report issued to clients and investors on Friday,Benzinga reports. They presently have a $29.00 target price on the biopharmaceutical company’s stock. HC Wainwright’s price target indicates a potential upside of 122.91% from the stock’s previous close. HC Wainwright also issued estimates for Dynavax Technologies’ Q4 2024 earnings at $0.04 EPS, FY2024 earnings at $0.18 EPS and FY2025 earnings at $0.26 EPS.

Separately, The Goldman Sachs Group reduced their target price on Dynavax Technologies from $20.00 to $15.00 and set a “neutral” rating on the stock in a research note on Thursday, August 8th.

Dynavax Technologies Stock Up 8.2 %

Shares of NASDAQ:DVAX opened at $13.01 on Friday. The stock’s 50-day moving average is $11.16 and its 200 day moving average is $11.24. The company has a market cap of $1.70 billion, a PE ratio of 118.28 and a beta of 1.34. The company has a debt-to-equity ratio of 0.35, a current ratio of 14.18 and a quick ratio of 13.18. Dynavax Technologies has a 1 year low of $9.74 and a 1 year high of $15.01.

Hedge Funds Weigh In On Dynavax Technologies

Institutional investors have recently bought and sold shares of the stock. Mizuho Markets Americas LLC lifted its position in Dynavax Technologies by 16.9% during the first quarter. Mizuho Markets Americas LLC now owns 852,057 shares of the biopharmaceutical company’s stock valued at $10,574,000 after buying an additional 123,300 shares during the period. Assenagon Asset Management S.A. bought a new position in shares of Dynavax Technologies in the 3rd quarter worth about $8,291,000. Millennium Management LLC purchased a new position in Dynavax Technologies during the 2nd quarter valued at about $17,615,000. Vanguard Group Inc. boosted its stake in Dynavax Technologies by 1.4% during the first quarter. Vanguard Group Inc. now owns 9,402,246 shares of the biopharmaceutical company’s stock worth $116,682,000 after acquiring an additional 126,458 shares in the last quarter. Finally, Bank of Montreal Can grew its holdings in Dynavax Technologies by 15.2% in the second quarter. Bank of Montreal Can now owns 994,632 shares of the biopharmaceutical company’s stock worth $11,309,000 after purchasing an additional 130,893 shares during the period. 96.96% of the stock is owned by institutional investors.

Dynavax Technologies Company Profile

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.